ArticleFrontiers in pharmacology2025
The impact of the national reimbursement drug list negotiation policy on the accessibility and utilization of evolocumab and alirocumab in different levels of hospitals: an interrupted time series analysis.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In December 2021, evolocumab and alirocumab were included in the National Reimbursement Drug List Negotiation (NRDLN), with implementation commencing in January 2022. This study aimed to evaluate the impact of the NRDLN policy on the clinical utilization of two novel lipid-lowering agents in different levels of hospitals. Methods: Data on evolocumab and alirocumab were collected from 910 tertiary and secondary public general hospitals across 31 provinces or autonomous regions in China (from January 2020 to December 2023) via the China Pharmaceutical Information Network (CPIN). Interrupted Time Series (ITS) analysis was employed to evaluate changes in drug availability, Defined Daily Doses (DDDs), and Defined Daily Dose cost (DDDc) before and after the inclusion of these drugs in the NRDLN. Results: The inclusion of evolocumab and alirocumab in the NRDLN was followed by a substantial increase in their availability, with alirocumab (β Conclusion: The inclusion of evolocumab and alirocumab in the NRDLN has significantly enhanced their accessibility and eased the medication burden on patients. Furthermore, the disparity in the adoption and utilization of PCSK9 inhibitors across hospital tiers has progressively narrowed, thereby safeguarding equitable health outcomes and advancing population health security.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.